Dynavax, a biotech company based in Berkley, Calif., will cut 82 jobs as part of a restructuring plan to prioritize its vaccine business, according to Biospace.
The layoffs will affect employees in research, clinical development and administrative roles.
In addition, Dynavac CEO Eddie Gray will step down from his role Aug. 1 as part of the restructuring effort.
The plan comes as the biotech works to shift its focus and resources from immuno-oncology and to vaccines, including its first commercial product, which is a hepatitis B vaccine.
Read the full report here.